PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Lori J. Wirth
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Gabriela Kornek
Honoraria - Amgen
Rita Axelrod
No relevant relationships to disclose
Douglas Adkins
No relevant relationships to disclose
Shubham Pant
No relevant relationships to disclose
Paul E. O'Brien
No relevant relationships to disclose
Philip R. Debruyne
No relevant relationships to disclose
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jun Dong
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Bruce A. Bach
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Research Funding - Amgen